- Home
- HLI vs QGEN Comparison
HLI vs QGEN Comparison
Compare HLI & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HLI | QGEN |
|---|---|---|
| Founded | 1972 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.6B | 10.2B |
| IPO Year | 2015 | 1998 |
Fundamental Metrics
Financial Performance| Metric | HLI | QGEN |
|---|---|---|
| Price | $152.03 | $40.94 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $194.29 | $51.30 |
| AVG Volume (30 Days) | 584.4K | ★ 1.6M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | 1.60% | ★ 5.88% |
| EPS Growth | ★ 41.61 | N/A |
| EPS | ★ 4.74 | N/A |
| Revenue | ★ $2,389,416,000.00 | N/A |
| Revenue This Year | $14.31 | $8.18 |
| Revenue Next Year | $12.52 | $5.71 |
| P/E Ratio | $31.70 | ★ $24.01 |
| Revenue Growth | ★ 24.81 | N/A |
| 52 Week Low | $134.41 | $38.80 |
| 52 Week High | $211.78 | $57.82 |
Technical Indicators
Market Signals| Indicator | HLI | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 58.93 | 43.47 |
| Support Level | $135.21 | $38.80 |
| Resistance Level | $197.84 | $49.11 |
| Average True Range (ATR) | 4.19 | 0.87 |
| MACD | 2.28 | 0.46 |
| Stochastic Oscillator | 95.64 | 72.53 |
Price Performance
Historical ComparisonAbout HLI Houlihan Lokey Inc.
Houlihan Lokey Inc is an investment bank with expertise in mergers and acquisitions, capital markets, financial restructuring, valuation, and strategic consulting. The firm serves corporations, institutions, and governments world-wide with offices in the United States, Europe, and the Asia-Pacific region. The company operates in three segments. In the Corporate Finance business segment, it provides M&A and capital markets advisory services. Through the Financial Restructuring business segment, the company advises on some of the complex restructurings around the world. The Financial and Valuation Advisory Services business segment provides valuation and financial opinion, and financial and strategic consulting practices in the United States.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).